IO | Jotup

Global Digital Oilfield Market to reach a valuation of US$ 70.1 billion by 2034, FMI Projection

Retrieved on:

Wednesday, February 21, 2024

Robotics, Algorithm, IO, Weatherford International, Integrated operations, Internet of things, CGG, Growth, ABB, Rockwell Automation, Schlumberger, Safety, Collaboration, FMI, Cloud computing, VR, Workforce, Software, Pet industry

NEWARK, Del., Feb. 21, 2024 /PRNewswire/ -- The global digital oilfield market is anticipated to reach a valuation of US$ 34.1 Billion in 2024, driven by integration of blockchain technology.

Key Points:

NEWARK, Del., Feb. 21, 2024 /PRNewswire/ -- The global digital oilfield market is anticipated to reach a valuation of US$ 34.1 Billion in 2024, driven by integration of blockchain technology.
Collaboration and partnerships among oil and gas companies, technology providers, and service vendors are driving innovation and accelerating the adoption of digital oilfield solutions.
Prominent players in the digital oilfield market are Schlumberger, Halliburton, Weatherford International, ABB, Emerson, CGG, Siemens, Rockwell Automation, and Kongsberg, among others.
Future Market Insights offers an unbiased analysis of the global digital oilfield market, providing historical data for 2019 to 2023 and forecast statistics from 2024 to 2034.

Vapor IO and Supermicro Launch Zero Gap™ AI, Powered by the NVIDIA GH200 Grace Hopper Superchip, in North America

Retrieved on:

Thursday, February 15, 2024

Vapor IO and Supermicro are today announcing a groundbreaking collaboration called Zero Gap™ AI, powered by the NVIDIA MGX platform with the NVIDIA GH200 Grace Hopper Superchip .

Key Points:

Vapor IO and Supermicro are today announcing a groundbreaking collaboration called Zero Gap™ AI, powered by the NVIDIA MGX platform with the NVIDIA GH200 Grace Hopper Superchip .
“Supermicro is excited to collaborate with Vapor IO and their Zero Gap AI platform,” said Don Clegg, senior vice president, Worldwide Sales, Supermicro.
High Reliability: Vapor IO’s Zero Gap network is designed for zero downtime and zero congestion to deliver consistent and uninterrupted service.
Zero Gap AI is now included in the integration work that Vapor IO and Comcast announced last year .

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

Retrieved on:

Tuesday, February 6, 2024

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.

Key Points:

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.
“For patients with relapsed or refractory advanced renal cell carcinoma, long-term progression-free survival is a vital measure of the value of anticancer therapy,” commented Michael Bailey, President and CEO of AVEO Oncology.
The trial randomized 350 patients to receive FOTIVDA (1.5 mg once daily) or sorafenib (400 mg twice daily).
The intent-to-treat (ITT) population included 175 patients in each arm; the safety population included 173 patients in the FOTIVDA arm and 170 in the sorafenib arm.

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Retrieved on:

Thursday, January 18, 2024

REDWOOD CITY, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC). These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California. Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment. Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.

Key Points:

These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California.
Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment.
Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.
Coherus plans to evaluate the combination of casdozo/toripalimab-tpzi(Coherus’ anti-PD-1 antibody)/bev in future clinical trials.

The State of the Biopharmaceutical Industry 2024: Genomics, IO Drug Development, Personalized/Precision Medicine and CGTs to Dominate as the Most Impactful Trends - ResearchAndMarkets.com

Retrieved on:

Monday, January 22, 2024

Biotechnology, Pharmaceutical, Health, IO, CGT, DSM-IV codes, AI, ESG, IRA, Infection, Genomics, Optimism, Drug development, COVID-19, Biopharmaceutical, CNS, Growth, Fine chemical

The State of the Biopharmaceutical Industry 2024 report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2024.

Key Points:

The State of the Biopharmaceutical Industry 2024 report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2024.
The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2024.
Genomics, IO drug development, personalized/precision medicine and CGTs will dominate as the most impactful trends in the biopharmaceutical industry in 2024.
Benchmark the impact of major themes on the biopharmaceutical industry in 2024, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends.

IO Interactive Welcomes Veronique Lallier as New Chief Development Officer

Retrieved on:

Wednesday, January 17, 2024

IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Veronique Lallier will be joining IOI as its new Chief Development Officer.

Key Points:

IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Veronique Lallier will be joining IOI as its new Chief Development Officer.
Operating globally across all studios and situated in Brighton which opened in July 2023, Veronique will be charged with overseeing IOI’s game development strategy and production.
View the full release here: https://www.businesswire.com/news/home/20240116212318/en/
"I'm excited to join IO Interactive, an iconic game studio with a 25-year legacy of maintaining high standards and creating globally recognized franchises.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers

GrubMarket Acquires JC Cheyne to Expand Further on the West Coast

Retrieved on:

Tuesday, January 16, 2024

Family, IO, E-commerce, San Francisco Bay Area, SAN, Onion, Culture, Ecosystem, Acquisition, Food industry, Jimmie, Financial management

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire/ -- GrubMarket announced today that it has completed the acquisition of Oregon and California-based JC Cheyne, a highly regarded fresh produce business that is widely known as the "wholesale house of the finest onions and potatoes in the Bay Area." JC Cheyne currently sells over 70 different items, including almost every color, size, and grade of potatoes and onions, to a diverse group of over 80 retail, food service, and wholesale establishments and mom-and-pop shops, across California. They also take pride in having great relationships with their suppliers in Oregon's Klamath Basin, Northwestern Washington, Idaho, and Mexico.

Key Points:

GrubMarket acquires Oregon and California-based JC Cheyne, a key provider of potatoes and onions in Northern California, to expand along the West Coast.
JC Cheyne was founded over 60 years ago by fresh produce veteran Jimmie Cheyne.
The entire JC Cheyne team treats each other like family, which aligns with GrubMarket's commitment to taking care of our people and partners.
With this acquisition, GrubMarket continues to strengthen our West Coast presence; I am thrilled to welcome JC Cheyne to the GrubMarket family."

Extremity Medical to Expand Orthopedic Extremity Implant Systems Through Strategic Relationship With Henry Schein as Well as Growth Financings

Retrieved on:

Thursday, January 11, 2024

Biotechnology, Physical Therapy, Finance, General Health, Health, Medical Devices, Banking, Professional Services, IO, Patient, Hand, Elective surgery, Foot, Ankle, Extremities, Marketing, Motion, Ageing, Medical device

This relationship will enable Extremity Medical to expand its innovative orthopedic extremity implant systems, enhancing healthcare outcomes for patients worldwide.

Key Points:

This relationship will enable Extremity Medical to expand its innovative orthopedic extremity implant systems, enhancing healthcare outcomes for patients worldwide.
In addition, Extremity Medical completed growth debt financings from June through November that will help fuel the Company’s growth.
Extremity Medical is known for designing, developing, and marketing innovative medical devices for extremity orthopedic procedures for fusion, fixation, and motion preservation.
"We are thrilled to work with Henry Schein in our journey to redefine extremity orthopedic care," said Matthew Lyons, CEO of Extremity Medical.

Peraton Awarded $889M Contract to Support U.S. Army Cyber Command (ARCYBER) and Cyber Mission Partners

Retrieved on:

Tuesday, January 9, 2024

EW, IO, ARCYBER, Policy, Intelligence, IAE, Environment, USCYBERCOM, Department of Defence, IWOC, Army, Information, Management

The work supports integration and conduct of cyberspace operations, electromagnetic warfare, and information operations to gain and maintain information advantage

Key Points:

The work supports integration and conduct of cyberspace operations, electromagnetic warfare, and information operations to gain and maintain information advantage
RESTON, Va., Jan. 9, 2024 /PRNewswire/ -- Peraton has won a competitive award to provide cyberspace operations support to U.S. Army Cyber Command (ARCYBER) headquarters, ARCYBER subordinate components, service component partners of USCYBERCOM, and other mission partners.
"The ARCYBER contract showcases the multi-faceted ability of Peraton to support the integration of cyberspace-related operations with EW, IO and other IAE activities to provide information advantage," said Tom Afferton, president, Cyber Mission sector.
The new work includes performing overall program management; operations and planning; intelligence support; cyber operations support; plans and policy support; information advantage operations support; media relations support; security operations; and training exercises.
Peraton will help ARCYBER gain information advantage that enables decision dominance in and through the cyberspace domain and the information dimension.

Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation

Retrieved on:

Monday, January 8, 2024

IO, Liver tumor, Physician, Software, LTD, FDA, RAZ, Literature, Radiology, CECT, Patient, De novo, Medical imaging

REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- Techsomed Medical Technologies LTD is thrilled to announce that FDA has granted De Novo clearance for its BioTraceIO, a groundbreaking ultrasound-based liver ablation software - designed for Tissue Response Prediction.

Key Points:

REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- Techsomed Medical Technologies LTD is thrilled to announce that FDA has granted De Novo clearance for its BioTraceIO, a groundbreaking ultrasound-based liver ablation software - designed for Tissue Response Prediction.
Ablation therapy, a minimally invasive treatment leveraging extreme temperatures, currently does not have tools available to predict the effect of ablation based on ultrasound.
BioTraceIO utilizes a unique computational algorithm to analyze ultrasound images captured during liver ablation treatment.
The integrated solution provides a comprehensive image-guided ablation visualization framework for eliminating guesswork typically associated with thermal ablation therapy.